Insmed Ownership
| INSM Stock | USD 74.09 0.94 1.29% |
Shares in Circulation | First Issued 2009-03-31 | Previous Quarter 155 M | Current Value 174 M | Avarage Shares Outstanding 68.6 M | Quarterly Volatility 43.4 M |
Please note, institutional investors have a lot of resources and new technology at their disposal. They can put in a lot of research and financial analysis when reviewing investment options. There are many different types of institutional investors, including banks, hedge funds, insurance companies, and pension plans. One of the main advantages they have over retail investors is the fees paid for trades. As they are buying in large quantities, they can manage their cost more effectively.
Insmed |
Insmed Stock Ownership Analysis
About 99.0% of the company shares are owned by institutional investors. The company recorded a loss per share of 5.55. Insmed Inc had not issued any dividends in recent years. The entity had 1:10 split on the 3rd of March 2011. Insmed Incorporated, a biopharmaceutical company, develops and commercializes therapies for patients with serious and rare diseases. Insmed Incorporated was founded in 1988 and is headquartered in Bridgewater, New Jersey. Insmed operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 613 people. To learn more about Insmed Inc call MBA JD at 908 977 9900 or check out https://www.insmed.com.Besides selling stocks to institutional investors, Insmed also allocates a substantial amount of its earnings to a pull of share-based compensation to be paid out to its employees, managers, executives, and members of the board of directors. Share-Based compensation (also sometimes called Stock-Based Compensation) is a way of paying different Insmed's stakeholders with equity in the business. It is typically used as a motivation factor for employees to contribute beyond their regular compensation (salary and bonus). It is also used as a tool to align Insmed's strategic interests with those of the company's shareholders. Shares issued to employees are usually subject to a vesting period before they are earned and sold.
Insmed Quarterly Liabilities And Stockholders Equity |
|
Insmed Insider Trades History
Less than 1% of Insmed Inc are currently held by insiders. Unlike Insmed's institutional investors, corporate insiders most likely have a limit on the maximum percentage of share ownership. This is done to align insiders' influence against Insmed's private investors even though both sides will benefit from rising prices or experience loss when the share price declines. The good rule to have in mind is that the maximum share ownership percentage of the corporate insiders should not surpass 25%. View all of Insmed's insider trades
Insmed Stock Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Insmed is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Insmed Inc backward and forwards among themselves. Insmed's institutional investor refers to the entity that pools money to purchase Insmed's securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Artisan Partners Limited Partnership | 2024-09-30 | 2.9 M | Macquarie Group Ltd | 2024-06-30 | 2.7 M | Franklin Resources Inc | 2024-09-30 | 2.7 M | Ameriprise Financial Inc | 2024-06-30 | 2.5 M | Suvretta Capital Management, Llc | 2024-06-30 | 2.5 M | Alliancebernstein L.p. | 2024-06-30 | 2.5 M | William Blair Investment Management, Llc | 2024-09-30 | 2.4 M | T. Rowe Price Investment Management,inc. | 2024-09-30 | 2.3 M | Hhg Plc | 2024-06-30 | 2.1 M | Vanguard Group Inc | 2024-09-30 | 17.1 M | Blackrock Inc | 2024-06-30 | 14.3 M |
Insmed Inc Insider Trading Activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Insmed insiders, such as employees or executives, is commonly permitted as long as it does not rely on Insmed's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Insmed insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Insmed's latest congressional trading
Congressional trading in companies like Insmed Inc, is subject to rigorous scrutiny to prevent conflicts of interest and insider trading. This is governed by multiple SEC regulations which were established to foster transparency and deter members of Congress from leveraging non-public information for personal gain. This oversight helps maintain public trust and ensures that investments in Insmed by those in governmental positions are based on the same information available to the general public.
| 2024-07-09 | Representative Josh Gottheimer | Acquired Under $15K | Verify | ||
| 2024-06-08 | Representative Josh Gottheimer | Acquired Under $15K | Verify |
Insmed Outstanding Bonds
Insmed issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Insmed Inc uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Insmed bonds can be classified according to their maturity, which is the date when Insmed Inc has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| Boeing Co 2196 Corp BondUS097023DG73 | View | |
| HSBC Holdings PLC Corp BondUS404280DR76 | View |
Insmed Corporate Filings
8K | 19th of November 2024 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
13A | 14th of November 2024 An amended filing to the original Schedule 13G | ViewVerify |
10Q | 31st of October 2024 Quarterly performance report mandated by Securities and Exchange Commission (SEC), to be filed by publicly traded corporations | ViewVerify |
F4 | 16th of September 2024 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Insmed Inc. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in state. You can also try the Portfolio Center module to all portfolio management and optimization tools to improve performance of your portfolios.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Insmed. If investors know Insmed will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Insmed listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (5.55) | Revenue Per Share 2.206 | Quarterly Revenue Growth 0.182 | Return On Assets (0.26) | Return On Equity (8.91) |
The market value of Insmed Inc is measured differently than its book value, which is the value of Insmed that is recorded on the company's balance sheet. Investors also form their own opinion of Insmed's value that differs from its market value or its book value, called intrinsic value, which is Insmed's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Insmed's market value can be influenced by many factors that don't directly affect Insmed's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Insmed's value and its price as these two are different measures arrived at by different means. Investors typically determine if Insmed is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Insmed's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.